Improving patient outcomes after lung cancer surgery using a mobile platform
Official title: Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Run by Shanghai Chest Hospital · NCT06483295 · Data updated 2026-11-12
This study is testing a mobile app to help lung cancer patients manage their recovery after surgery by tracking symptoms and improving communication with their doctors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 216 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 24, 2024 |
| Main results expected | July 7, 2024 |
| Study ends | December 31, 2026 |
| Registry record updated | May 28, 2025 |
| Trial ID | NCT06483295 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients diagnosed with Stage I-III lung cancer who have undergone surgical resection and are familiar with using WeChat on their smartphones.
✕Probably not a fit
Patients who have received non-surgical anti-tumor therapies or have serious comorbidities that prevent them from undergoing surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the management of postoperative symptoms in lung cancer patients through a mobile internet platform integrated with WeChat. By focusing on patient-reported outcomes (PROs), the research seeks to monitor symptoms like pain and coughing more effectively, thereby improving patient engagement and follow-up care. The study will create a prospective database to analyze factors affecting recovery and assess the role of interactive platforms in enhancing patient care. The use of internet technology is expected to facilitate better communication between patients and healthcare providers post-surgery.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and recovery outcomes for lung cancer patients after surgery.
How similar studies have gone: While the use of mobile platforms for patient engagement is gaining traction, this specific approach focusing on lung cancer postoperative care is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed with Stage I-III lung cancer and surgically resected at our centre. 2. Owns and uses a smartphone and can use WeChat. 3. Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: 1. Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period. 2. After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen. 3. After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge. 4. At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Where it's running
-
Zuodong Song
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Xinghua Cheng, MD — Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Study coordinator: Xinghua Cheng, MD
- Email: chengxinghua_001@163.com
- Phone: +8617701681215
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.